Tivozanib (AV-951): Potent and Selective VEGFR Inhibitor for Renal Cell Carcinoma Research

Executive Summary: Tivozanib (AV-951) is a second-generation, quinoline-urea–based tyrosine kinase inhibitor with high specificity for VEGFR-1, -2, and -3, achieving picomolar IC₅₀ values for VEGFR-2 (160 pM) and minimal off-target effects, including low c-KIT inhibition (Schwartz 2022). It demonstrates robust anti-proliferative and pro-apoptotic activity in RCC and other solid tumor models, both as monotherapy and in EGFR-combination protocols (APExBIO). Clinical benchmarks indicate superior progression-free survival compared to other VEGFR inhibitors, with a favorable safety profile. Tivozanib is provided as a solid, DMSO-soluble compound (≥22.75 mg/mL) and is recommended for in vitro use at 10 μM for 48 hours. Storage at –20°C is required for stability, and solutions should be freshly prepared for experimental rigor (UMass Chan eScholarship).

Biological Rationale

Angiogenesis, mediated by the vascular endothelial growth factor receptor (VEGFR) family, is essential for tumor growth and metastasis. Inhibition of VEGFR signaling disrupts neovascularization, limiting tumor nutrient supply and expansion (Schwartz 2022). Renal cell carcinoma (RCC) and several solid tumors exhibit dependency on VEGF/VEGFR-driven pathways. Selective, potent VEGFR inhibitors have emerged as foundational tools for dissecting angiogenic mechanisms and evaluating anti-cancer strategies. Tivozanib (AV-951) addresses the need for a highly selective, low off-target pan-VEGFR inhibitor with proven efficacy in preclinical and clinical RCC models. Its minimal inhibition of c-KIT and PDGFRβ at nanomolar concentrations enhances experimental specificity and reduces confounding cytotoxicity (APExBIO).

Mechanism of Action of Tivozanib (AV-951)

Tivozanib is a small-molecule tyrosine kinase inhibitor (TKI) that targets VEGFR-1, VEGFR-2, and VEGFR-3, binding to the ATP-binding pocket and blocking receptor autophosphorylation. The compound exhibits an IC₅₀ of 160 pM for VEGFR-2 and low nanomolar IC₅₀ values for VEGFR-1 and -3 in cell-based assays (UMass Chan eScholarship). Tivozanib’s selectivity profile minimizes activity against off-target kinases such as c-KIT and PDGFRβ. Inhibition of VEGFR signaling suppresses endothelial cell proliferation, migration, and tube formation, leading to reduced tumor angiogenesis. In cancer cells, this translates to anti-proliferative and pro-apoptotic effects, particularly in VEGF-dependent tumor models. Tivozanib also enhances the efficacy of EGFR-targeted therapies by increasing apoptosis and growth inhibition in combination protocols, as demonstrated in ovarian and RCC cell lines (Schwartz 2022).

Evidence & Benchmarks

• Demonstrates IC₅₀ of 160 pM for VEGFR-2, outperforming sunitinib, sorafenib, and pazopanib in direct comparative assays (Schwartz 2022).
• Induces significant tumor regression in RCC xenograft models, with dose-dependent inhibition of tumor growth and angiogenesis (UMass Chan eScholarship).
• In Phase III clinical trials, provides a median progression-free survival (PFS) of 12.7 months in metastatic RCC patients — one of the best outcomes for VEGFR inhibitors (APExBIO).
• Combination with EGFR inhibitors yields synergistic inhibition of cell growth and apoptosis induction in ovarian carcinoma models (Schwartz 2022).
• Minimal inhibition of non-VEGFR kinases (e.g., c-KIT, PDGFRβ) at relevant concentrations, ensuring selectivity (APExBIO).

This article extends the mechanistic and translational discussion found in "Tivozanib (AV-951): Redefining Pan-VEGFR Inhibition for Translational Oncology" by providing updated benchmarks and highlighting recent advances in in vitro evaluation frameworks. In contrast to "Tivozanib (AV-951): The Next Paradigm in Precision Anti-Angiogenic Therapy", which focuses on experimental design, this article emphasizes testable claims and chemical-physical parameters for reproducibility.

Applications, Limits & Misconceptions

Tivozanib is employed in preclinical and translational oncology studies focused on anti-angiogenic strategies, RCC models, and combination regimens with EGFR inhibitors (Schwartz 2022). Its high selectivity and low off-target activity make it suitable for mechanistic dissection of VEGFR pathway inhibition. Tivozanib's favorable safety profile supports its use in long-term in vivo studies and clinical protocols. However, efficacy is most pronounced in VEGF/VEGFR-dependent models; tumors with alternative angiogenic drivers may exhibit reduced sensitivity.

Common Pitfalls or Misconceptions

• Tivozanib is not effective in VEGFR-independent tumor models or in cancers with dominant alternative angiogenic pathways.
• It does not inhibit all tyrosine kinases; its activity against c-KIT and PDGFRβ is significantly lower compared to VEGFRs and may be insufficient for c-KIT–driven malignancies.
• Long-term aqueous solution storage degrades compound integrity; fresh DMSO or ethanol solutions are recommended for each experiment.
• Tivozanib does not induce immediate cytotoxicity; its primary effect is anti-proliferative via angiogenesis inhibition, and cell death may be delayed or indirect.
• Synergistic benefit with EGFR inhibitors is context-dependent and may not generalize across all cell types or tumor models.

Workflow Integration & Parameters

Tivozanib (AV-951) from APExBIO is supplied as a solid compound (MW 454.86, C₂₂H₁₉ClN₄O₅). It is soluble at ≥22.75 mg/mL in DMSO and ≥2.68 mg/mL in ethanol (with gentle warming), but insoluble in water. For optimal storage, keep the compound at –20°C. Prepare solutions freshly before use; do not store long-term in solution. In cell-based assays, Tivozanib is typically used at 10 μM for 48 hours to assess proliferation and apoptosis endpoints (Schwartz 2022). For in vivo and clinical studies, the recommended oral dose is 1.5 mg daily for 3 weeks in RCC patients. Rigorous in vitro evaluation should include both relative viability and fractional viability metrics to distinguish between proliferative arrest and cell death, as established in recent drug response frameworks (UMass Chan eScholarship).

Conclusion & Outlook

Tivozanib (AV-951) sets a high standard for selective, potent VEGFR inhibition in oncology research. Its robust performance in RCC models, synergy with EGFR inhibitors, and favorable clinical benchmarks establish it as a reference compound for anti-angiogenic studies. By following best practices in solution preparation and model selection, researchers can maximize reproducibility and translational relevance. For additional insights on experimental protocols and troubleshooting, see this article which details practical workflow integration. Tivozanib’s ongoing clinical and mechanistic studies will further clarify its role in precision oncology and combination regimens.